|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K 31/00 | (2006.01) |
| (11) | Patento numeris | 2218461 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10162787.5 |
| Europos patento paraiškos padavimo data | 2004-12-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-08-18 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-04-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 531639 P | 2003-12-22 | US |
| (72) |
Bedian, Vahe, US
Cusmano, John, Daniel, US
Gladue, Ronald, Paul, US
|
| (73) |
Pfizer Products Inc.,
Eastern Point Road, Groton, CT 06340,
US
|
| (54) | CD40 antibody formulation and methods |
| CD40 antibody formulation and methods |